Evidence mapPaperPMID 42021362Full record

ReviewBMC biology2026

Fusion oncogenes in cancer: organoid models and novel therapeutic approaches.

Lucia Bracesco, Delilah Hendriks, Benedetta Artegiani

Abstract readReview
In one paragraph

Review in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lucia BracescoPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Delilah Hendriks *Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. d.f.g.hendriks-7@prinsesmaximacentrum.nl.
Benedetta Artegiani *Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. b.a.artegiani@prinsesmaximacentrum.nl.

Funding

HORIZON EUROPE Marie Sklodowska-Curie Actions co-fund project number 101081481
6 · The paper itself

Abstract

Oncogenic fusions, arising from chromosomal rearrangements, occur in several cancers, particularly in those of pediatric origin. Advances in sequencing technologies have improved fusion detection; yet, understanding their mechanisms and tumorigenic potential remains challenging. This is partly due to the limited availability of faithful human-based model systems. Organoids have emerged as a physiologically relevant model system with in vivo-like traits and have recently allowed to obtain novel mechanistic and therapeutic insights for oncogenic fusion-bearing cancers. This review discusses how, through bottom-up tumor modeling as well as tumoroid derivation, these models are being employed to increase our understanding of fusion-bearing cancers, and how they can help future therapeutic discovery for these tumors.

Indexed as

NeoplasmsOncogene FusionOncogenesOrganoidsAnimalsHumansModels, BiologicalCancerOncofusionsOncogenesOrganoidsTumoroids

Identifiers

PMID42021362
PMCPMC13235106

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.